--- title: Walgreens 2024: how Tim Wentworth took the CEO role and announced 1,200 store closures while exploring private-equity sale of the entire company | RGM® url: https://realgrowthmatters.com/learn/case-studies/walgreens-brand-repositioning-campaign/ updated: 2026-06-10 source_html: https://realgrowthmatters.com/learn/case-studies/walgreens-brand-repositioning-campaign/ --- - **Story:** Walgreens Boots Alliance had compounding structural deterioration through 2018-2024: January 2024 dividend cut (~48% reduction; first cut in 50+ consecutive years), August 2024 strategic-alternatives review, October 2024 announcement of ~1,200 store closures over three years (~14% of US footprint), and December 2024 reports of Sycamore Partners take-private discussions. Drivers: VillageMD healthcare bet writedowns ($5.2B+ cumulative), pharmacy reimbursement pressure, front-of-store retail decline, Amazon Pharmacy competitive emergence, Boots international segment underperformance. Stock declined ~90% from 2015 peak to 2024 trough. Tim Wentworth (CEO since October 2023) inherited difficult structural challenges. - **Why it matters:** Walgreens 2018-2024 is the worked example of legacy-retail strategic decline despite leadership attempts: failed healthcare integration, prolonged dividend defense, insufficient competitive response combine into near-existential threat. - **Takeaway:** Accumulated structural pressures compound; individual operational responses are usually insufficient when multiple structural pressures combine. - **Takeaway:** Prolonged dividend defense at expense of strategic flexibility can compound financial position deterioration. - **Takeaway:** Strategic alternatives (take-private, break-up, segment divestiture) may be necessary when operational responses can't address structural decline. ## Walgreens 2024 retrenchment — the four-step story S Situation Walgreens accumulated structural pressures (VillageMD failure, pharmacy reimbursement compression, retail decline, Amazon competition) Through 2018-2023, multiple structural pressures combined: PBM reimbursement compression, front-of-store retail decline, Amazon Pharmacy emergence, VillageMD healthcare bet underperformance. By 2023 the dividend was unsustainable, stock had declined sharply, and CEO Roz Brewer departed. Tim Wentworth was appointed October 2023 to stabilize. T Task Cut dividend, close stores, evaluate strategic alternatives, manage VillageMD writedowns Execute dividend cut (~48%, January 2024) to free capital flexibility. Announce 1,200 store closures (October 2024). Conduct strategic-alternatives review (August 2024). Continue VillageMD writedowns and market exits. Engage with potential take-private acquirers. Maintain operational discipline through period of uncertainty. A Action January 2024 dividend cut; August 2024 strategic review; October 2024 store closures; December 2024 Sycamore discussions reported Tim Wentworth's first 14 months executed multi-front response. Each strategic action was necessary but reflected accumulated rather than recent strategic-direction errors. The Sycamore Partners discussion represents potential end of Walgreens's 90+ year public-company history. Strategic-alternative outcomes uncertain through 2025. R Result Multi-front strategic retrenchment in progress; take-private deal could materially change company structure; structural decline persists Walgreens 2024 chapter represents culmination of multi-year structural deterioration. Strategic alternatives being evaluated. Take-private deal possible but uncertain. Long-term company structure (continued public operation vs private ownership vs major segment divestitures) will be determined through 2025. Pharmacy-sector structural pressures will continue regardless of corporate structure. ## Walgreens 2024 retrenchment at a glance ~0 Store closures over 3 years ~14% of US footprint; announced October 2024 Source: Walgreens announcement $0 Stock 2015 peak to 2024 trough ~90% decline Source: NASDAQ WBA historical 0% January 2024 dividend cut First cut in 50+ consecutive annual-increase years Source: Walgreens dividend history $0B+ Cumulative VillageMD writedowns Through 2023-2024 Source: Walgreens SEC filings 0 Tim Wentworth CEO start From Evernorth/Express Scripts (Cigna) Source: Walgreens announcement 0 Sycamore Partners discussions reported Potential take-private; terms uncertain Source: WSJ reporting #### Quick facts CompanyWalgreens Boots Alliance, Inc. (NASDAQ: WBA) CEOTim Wentworth (since October 23, 2023) 2024 store closures announced~1,200 over three years (~14% of US footprint) January 2024 dividend cut~48% reduction; first cut in 50+ years VillageMD writedowns 2023-2024$5.2B+ cumulative Stock decline from 2015 peakFrom ~$95 to ~$9 (~90% decline) December 2024 take-private explorationSycamore Partners discussions reported 2023 revenue$139.1B **Honest note** Walgreens's deterioration is one of the most dramatic retail-sector value-destruction stories of recent history. The accumulated mistakes (VillageMD healthcare bet, slow response to pharmacy-sector pressure, international segment underperformance) have compounded. The potential Sycamore take-private would end Walgreens's 90+ year history as an independent public company. Tim Wentworth's 14-month tenure has been structurally challenging; whether any leadership could have done substantially better is uncertain. The case here describes 2024 events; final outcome (take-private vs continued public operation vs further deterioration) will be determined through 2025. ## The Walgreens deterioration arc Walgreens's structural decline accelerated through 2018-2024: - **2014-2015 peak**: Walgreens stock peaked above $95 after the Alliance Boots merger (December 2014) created the integrated Walgreens Boots Alliance. The combined company seemed positioned for international growth and integrated retail-pharmacy scale. - **2018 Amazon Pharmacy emergence**: Amazon's PillPack acquisition (June 2018, ~$753M) signaled Amazon's entry into prescription delivery. Stefano Pessina (CEO 2015-2021) acknowledged Amazon as competitive threat. - **2020-2022 pandemic-era cycle**: pandemic produced temporary vaccination revenue surge that masked underlying retail-pharmacy economic deterioration. - **October 2020 VillageMD investment**: Walgreens invested $1B+ in VillageMD for primary-care clinic partnership; subsequent additional investment grew Walgreens stake to majority. - **March 2022 Walgreens majority VillageMD acquisition**: $5.2B additional investment took Walgreens to ~63% ownership of VillageMD. Strategic logic: integrate primary care with retail pharmacy. - **2022-2023 deterioration continues**: pharmacy reimbursement compression, front-of-store retail decline, VillageMD operating losses, Boots underperformance compound. - **October 2023 Tim Wentworth appointed CEO**: from Evernorth (Cigna's PBM/Express Scripts). Replacing Roz Brewer (CEO 2021-2023). Mandate: stabilize operations. ## The 2024 events and the strategic retrenchment Wentworth's first year as CEO produced major strategic announcements: - **January 2024 dividend cut (~48%)**: from $0.48 to $0.25 quarterly. First dividend cut in over 50 consecutive years. The cut was substantial but probably should have happened earlier; the prolonged dividend defense had compounded the company's financial position. - **VillageMD writedowns continued**: cumulative impairments through 2023-2024 totaled approximately $5.2B+ on the VillageMD investments. Walgreens announced exit from selected VillageMD markets. - **Q3 fiscal 2024 (May 2024 reporting) earnings disappointment**: continued pharmacy reimbursement pressure, front-of-store sales decline. Wentworth signaled major strategic review. - **August 2024 announcement of strategic alternatives review**: Walgreens publicly indicated it was reviewing options including selling parts of the business. - **October 2024 announcement of 1,200 store closures**: approximately 14% of US footprint over three years. Closures concentrated in underperforming locations. - **December 2024 Sycamore Partners discussions**: WSJ reported Walgreens was in discussions with Sycamore Partners about potential take-private deal. Specific terms and timing not committed; discussions could fail. ## The VillageMD strategic mistake The VillageMD healthcare bet has been the major strategic error of recent Walgreens history: - **Original 2020 thesis**: integrate primary-care clinics with retail pharmacy to provide one-stop healthcare destination. Strategic logic similar to CVS-MinuteClinic but more aggressive. - **Investment scale**: Walgreens invested $1B+ initially (October 2020) and additional $5.2B in March 2022 to acquire majority ownership of VillageMD plus support continued clinic expansion. Plans called for 1,000+ VillageMD clinics co-located with Walgreens stores. - **VillageMD operating losses**: clinics produced substantial operating losses that didn't improve. Primary-care economics required Medicare Advantage and value-based care contracts that VillageMD struggled to scale. - **Summit Health acquisition (2023)**: VillageMD acquired Summit Health for $9B+ further expanding the business, but integration was difficult. - **Walgreens writedowns 2023-2024**: cumulative impairments approached $5.2B+ as actual VillageMD performance fell far short of original projections. - **Strategic exit**: Walgreens announced 2024 exit from selected VillageMD markets. Whether VillageMD will continue as Walgreens-controlled business or be divested separately is open question. ## The Sycamore Partners take-private question The December 2024 reports of Sycamore Partners discussions represent potential end of Walgreens's public-company status: - **Sycamore Partners**: private-equity firm with substantial retail-investment history (Talbots, Staples retail, Belk, others). Specialized in legacy-retail restructuring. - **Potential transaction structure**: take-private deal would acquire Walgreens stock at premium to depressed 2024 levels. Specific terms not publicly committed. - **Strategic implications**: private ownership would allow more aggressive restructuring (additional store closures, business-segment divestitures, employee reductions) without public-market scrutiny. - **Boots international segment**: Sycamore could pursue Boots divestiture (UK pharmacy retail) as separate transaction. - **Pharmacy retail consolidation**: take-private could be precursor to broader US pharmacy-sector consolidation; CVS continues retail challenges, Rite Aid emerged from Chapter 11 with reduced footprint. - **Wentworth role**: under private-equity ownership, CEO continuity uncertain. Some PE acquisitions retain existing management; others replace it. - **Outcome uncertainty**: discussions could fail; specific terms might not be agreed; potential antitrust review for any major pharmacy-sector consolidation. ## How RGM thinks about legacy-retail strategic decline Walgreens 2018-2024 is the worked example of legacy-retail strategic decline despite operational and strategic-leadership attempts. The structural elements that produced compounding deterioration: failed healthcare integration bet (VillageMD) at substantial cost; prolonged dividend defense at expense of strategic flexibility; insufficient response to Amazon Pharmacy competitive emergence; PBM economic pressure that compressed pharmacy margins; front-of-store retail decline. Each individual pressure was manageable; combined they produced near-existential threat to company structure. Our framework for clients in legacy-retail-pharmacy or adjacent sectors: when accumulated structural pressures combine, individual operational responses are insufficient. Walgreens's January 2024 dividend cut should have happened earlier; the VillageMD investment scale should have been smaller or reversed faster; the response to Amazon Pharmacy should have been more aggressive product or service differentiation. We tell clients in similar legacy-sector situations to honestly evaluate accumulated pressures earlier rather than later, and to consider strategic alternatives (sale, take-private, major segment divestiture) when operational responses can't address the underlying structural deterioration. Walgreens's potential Sycamore take-private may be the late strategic-alternative recognition; the financial and strategic damage in the interim has been substantial. ## Frequently asked questions Will the Sycamore take-private actually happen? Genuinely uncertain. Discussions were reported December 2024; specific terms and timeline not committed. Potential complications include shareholder vote (required for any take-private), Walgreens debt complexity, antitrust review for major pharmacy-sector transaction, and Sycamore's ability to fund the deal. Most analyst expectations suggest deal could close in 2025 if terms are agreed; could also fall apart for various reasons. Is Walgreens fundamentally fixable? Difficult. Pharmacy-sector economics are structurally pressured (PBM reimbursement, Amazon competition, front-of-store decline). Walgreens's specific accumulated issues (VillageMD writedowns, dividend cuts, leverage) compound the structural sector challenges. Tim Wentworth's operational discipline can stabilize but unlikely to reverse the structural pressure. Major structural change (take-private, break-up, separation of Boots) may be necessary regardless of leadership. What about Boots in the UK? Underperforming the broader Walgreens portfolio. Boots international segment (primarily UK pharmacy retail) has faced its own challenges including UK economic pressure, online prescription delivery competition, and currency translation effects. Sycamore Partners could pursue Boots divestiture as separate transaction post-take-private. Walgreens had attempted Boots divestiture in 2022 but the process produced no acceptable offers. What's CVS competitive position vs Walgreens now? Both deteriorating but CVS's situation is structurally better. CVS has Aetna insurance and Caremark PBM segments that produce diversified revenue; Walgreens lacks comparable diversification. Both face retail-pharmacy pressure but CVS has more integrated value chain. Both 2024 CEO transitions (Karen Lynch to David Joyner at CVS, Roz Brewer to Tim Wentworth at Walgreens) reflect leadership-credibility pressure. The pharmacy-sector deterioration is sector-wide, not company-specific. Is there any positive story for Walgreens? Limited but not zero. Pharmacy services that integrate with insurance and provider networks have continued growth. International segments produce some positive contribution. Specialty pharmacy operations have growth potential. But the core retail-pharmacy business faces structural deterioration that overwhelms positive contributions from adjacent segments. Stock has stabilized at depressed levels through 2024; structural recovery in any direction will take years. ### Sources & references - [Tim Wentworth CEO appointment](https://news.walgreens.com/press-center/news/tim-wentworth-named-ceo.html) — Walgreens October 2023 announcement. - [Store closures announcement](https://news.walgreens.com/press-center/news/walgreens-store-closures-2024.html) — Walgreens October 2024 announcement. - [Sycamore Partners take-private coverage](https://www.wsj.com/business/retail/walgreens-sycamore-partners-take-private-2024-12-10) — WSJ coverage of December 2024 discussions. - [Walgreens investor relations](https://investor.walgreensbootsalliance.com/financial-information/sec-filings) — Walgreens SEC filings and earnings. - [VillageMD strategic context](https://www.ft.com/content/walgreens-villagemd-healthcare-strategic-mistake-2024) — FT coverage of VillageMD bet outcomes. ## Related [#### All case studies The full case-study library.](/learn/case-studies/)[#### CVS Health 2024 Adjacent pharmacy-sector case (more diversified structure).](/learn/case-studies/cvs-brand-repositioning-campaign/)[#### AT&T post-WBD refocus Adjacent post-strategic-mistake case.](/learn/case-studies/at-t-brand-repositioning-campaign/)[#### Best Buy turnaround Contrast: retail-sector successful turnaround.](/learn/case-studies/best-buy-turnaround-hubert-joly-2012-2019/)